Compare CPT & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPT | HALO |
|---|---|---|
| Founded | 1993 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3B | 11.2B |
| IPO Year | 1995 | 2001 |
| Metric | CPT | HALO |
|---|---|---|
| Price | $107.46 | $107.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 11 |
| Target Price | ★ $115.28 | $78.64 |
| AVG Volume (30 Days) | 867.7K | ★ 2.3M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.03% | N/A |
| EPS Growth | ★ 136.00 | N/A |
| EPS | 0.59 | ★ 3.11 |
| Revenue | $12,967,000.00 | ★ $151,862,000.00 |
| Revenue This Year | N/A | $28.24 |
| Revenue Next Year | $2.60 | $12.56 |
| P/E Ratio | $182.92 | ★ $34.12 |
| Revenue Growth | ★ 81.69 | N/A |
| 52 Week Low | $96.53 | $61.23 |
| 52 Week High | $119.81 | $107.96 |
| Indicator | CPT | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 39.69 | 78.97 |
| Support Level | $105.41 | $67.12 |
| Resistance Level | $111.82 | N/A |
| Average True Range (ATR) | 1.84 | 3.59 |
| MACD | -0.30 | 0.96 |
| Stochastic Oscillator | 2.87 | 98.87 |
Camden Property Trust is a real estate investment trust engaged in the ownership, management, development, reposition, redevelopment, acquisition, and construction of multifamily apartment communities. It owned interests in, operated, or developing nearly 175 multifamily properties comprised of nearly 59,921 apartment homes across the United States.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.